HomeAI · summaries
Storia in 3 fonti
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Cipla said its US unit has entered an exclusive partnership with Chinas Qilu Pharmaceutical to license QL2107, a biosimilar of Mercks cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Cipla partners with Qilu Pharmaceutical for Keytruda biosimilar in US
Cipla’s wholly owned US subsidiary Invagen Pharmaceuticals has partnered with Qilu Pharmaceutical to license and supply QL2107, a pembrolizumab biosimilar, for marketing in the…
- ·
economictimes.indiatimes.com
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Cipla said its US unit has entered an exclusive partnership with Chinas Qilu Pharmaceutical to license QL2107, a biosimilar of Mercks cancer drug Keytruda. Qilu will handle…
